247 related articles for article (PubMed ID: 30285518)
1. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD; Linossi C; Middleton M; Lord S; Harris A; Rodón J; Zitt C; Fiedler U; Dawson KM; Leupin N; Stumpp MT; Harstrick A; Azaro A; Fischer S; Omlin A
J Clin Oncol; 2021 Jan; 39(2):145-154. PubMed ID: 33301375
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Kollmannsberger C; Britten CD; Olszanski AJ; Walker JA; Zang W; Willard MD; Radtke DB; Farrington DL; Bell-McGuinn KM; Patnaik A
Invest New Drugs; 2021 Dec; 39(6):1613-1623. PubMed ID: 34264412
[TBL] [Abstract][Full Text] [Related]
6. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.
Hong DS; Rosen P; Lockhart AC; Fu S; Janku F; Kurzrock R; Khan R; Amore B; Caudillo I; Deng H; Hwang YC; Loberg R; Ngarmchamnanrith G; Beaupre DM; Lee P
Oncotarget; 2015 Jul; 6(21):18693-706. PubMed ID: 26155941
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Keam B; Ock CY; Kim TM; Oh DY; Kang WK; Park YH; Lee J; Lee JH; Ahn YH; Kim HJ; Chang SK; Park J; Choi JY; Song YJ; Park YS
Invest New Drugs; 2021 Dec; 39(6):1624-1632. PubMed ID: 34268711
[TBL] [Abstract][Full Text] [Related]
8. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Kondo S; Katsuya Y; Yonemori K; Komuro K; Sugeno M; Kawata T; Ghiorghiu D; Meulendijks D; Yamamoto N
Cancer Treat Res Commun; 2024; 39():100809. PubMed ID: 38593512
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz MA; Landau H; Comenzo RL; Seldin D; Weiss B; Zonder J; Merlini G; Schönland S; Walling J; Kinney GG; Koller M; Schenk DB; Guthrie SD; Liedtke M
J Clin Oncol; 2016 Apr; 34(10):1097-103. PubMed ID: 26858336
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Tolcher AW; Berlin JD; Cosaert J; Kauh J; Chan E; Piha-Paul SA; Amaya A; Tang S; Driscoll K; Kimbung R; Kambhampati SR; Gueorguieva I; Hong DS
Cancer Chemother Pharmacol; 2017 Apr; 79(4):673-680. PubMed ID: 28280971
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.
Li S; Zhang D; Sun J; Li Z; Deng L; Zou B; Zhan J; Jiang W
MAbs; 2012; 4(2):256-66. PubMed ID: 22453099
[TBL] [Abstract][Full Text] [Related]
15. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Bendell J; LoRusso P; Overman M; Noonan AM; Kim DW; Strickler JH; Kim SW; Clarke S; George TJ; Grimison PS; Barve M; Amin M; Desai J; Wise-Draper T; Eck S; Jiang Y; Khan AA; Wu Y; Martin P; Cooper ZA; Elgeioushi N; Mueller N; Kumar R; Patel SP
Cancer Immunol Immunother; 2023 Jul; 72(7):2443-2458. PubMed ID: 37016126
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Pishvaian MJ; Marshall JL; Wagner AJ; Hwang JJ; Malik S; Cotarla I; Deeken JF; He AR; Daniel H; Halim AB; Zahir H; Copigneaux C; Liu K; Beckman RA; Demetri GD
Cancer; 2012 Nov; 118(21):5403-13. PubMed ID: 22570147
[TBL] [Abstract][Full Text] [Related]
17. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Rasco DW; Papadopoulos KP; Pourdehnad M; Gandhi AK; Hagner PR; Li Y; Wei X; Chopra R; Hege K; DiMartino J; Shih K
Clin Cancer Res; 2019 Jan; 25(1):90-98. PubMed ID: 30201761
[TBL] [Abstract][Full Text] [Related]
18. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.
Hong D; Said R; Falchook G; Naing A; Moulder S; Tsimberidou AM; Galluppi G; Dakappagari N; Storgard C; Kurzrock R; Rosen LS
Clin Cancer Res; 2013 Sep; 19(17):4824-31. PubMed ID: 23873691
[TBL] [Abstract][Full Text] [Related]
20. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Woodcock VK; Clive S; Wilson RH; Coyle VM; Stratford MRL; Folkes LK; Eastell R; Barton C; Jones P; Kazmi-Stokes S; Turner H; Halford S; Harris AL; Middleton MR
Br J Cancer; 2018 Mar; 118(6):770-776. PubMed ID: 29438361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
